Patents by Inventor Ernie De Boer

Ernie De Boer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody production
    Patent number: 9980470
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 29, 2018
    Assignee: Erasmus University Medical Center
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen, Roger Kingdon Craig, Ernie De Boer
  • Soluble heavy-chain only antibodies
    Patent number: 9365655
    Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 14, 2016
    Assignee: Erasmus University Medical Center
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
  • ANTIBODY PRODUCTION
    Publication number: 20140356907
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 4, 2014
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS, MARINUS JOHANNES VAN HAPEREN, ROGER KINGDON CRAIG, ERNIE DE BOER
  • Soluble “heavy-chain only” antibodies
    Patent number: 8883150
    Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: November 11, 2014
    Assignee: Erasmus University Medical Center
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
  • SOLUBLE "HEAVY-CHAIN ONLY" ANTIBODIES
    Publication number: 20120151610
    Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and an increased number of charged amino acids present in FR3. Also provided are VII domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.
    Type: Application
    Filed: March 19, 2010
    Publication date: June 14, 2012
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer